IS8231A - Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða - Google Patents

Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða

Info

Publication number
IS8231A
IS8231A IS8231A IS8231A IS8231A IS 8231 A IS8231 A IS 8231A IS 8231 A IS8231 A IS 8231A IS 8231 A IS8231 A IS 8231A IS 8231 A IS8231 A IS 8231A
Authority
IS
Iceland
Prior art keywords
carboxylic acid
acid derivatives
pharmaceutically useful
useful salts
salts
Prior art date
Application number
IS8231A
Other languages
English (en)
Inventor
Aurell Carl-Johan
Dahlström Mikael
Lindstedt-Alstermark Eva-Lotte
Minidis Anna
Ohlsson Bengt
Ståhle Erica
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8231A publication Critical patent/IS8231A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS8231A 2003-06-18 2006-01-13 Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða IS8231A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314129.8A GB0314129D0 (en) 2003-06-18 2003-06-18 Therapeutic agents
PCT/SE2004/000964 WO2004110984A1 (en) 2003-06-18 2004-06-16 Pharmaceutically useful salts of carboxylic acid derivates

Publications (1)

Publication Number Publication Date
IS8231A true IS8231A (is) 2006-01-13

Family

ID=27636788

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8231A IS8231A (is) 2003-06-18 2006-01-13 Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða

Country Status (23)

Country Link
US (1) US20060142389A1 (is)
EP (1) EP1638922A1 (is)
JP (1) JP3822900B1 (is)
KR (1) KR20060027348A (is)
CN (1) CN1809529A (is)
AR (1) AR044801A1 (is)
AU (1) AU2004247610B2 (is)
BR (1) BRPI0411525A (is)
CA (1) CA2528932A1 (is)
CO (1) CO5650228A2 (is)
GB (1) GB0314129D0 (is)
IL (1) IL172167A0 (is)
IS (1) IS8231A (is)
MX (1) MXPA05013714A (is)
MY (1) MY137277A (is)
NO (1) NO20055922L (is)
RU (1) RU2005138590A (is)
SA (1) SA04250169B1 (is)
TW (1) TW200503677A (is)
UA (1) UA81807C2 (is)
UY (1) UY28375A1 (is)
WO (1) WO2004110984A1 (is)
ZA (1) ZA200510252B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
BR0311932A (pt) 2002-06-20 2005-03-22 Astrazeneca Ab Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
NO2686520T3 (is) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2219172C2 (ru) * 1999-04-06 2003-12-20 Санкио Компани, Лимитед α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
RU2005138590A (ru) 2006-07-27
BRPI0411525A (pt) 2006-08-01
SA04250169A (ar) 2005-12-03
CO5650228A2 (es) 2006-06-30
MY137277A (en) 2009-01-30
AU2004247610A1 (en) 2004-12-23
IL172167A0 (en) 2009-02-11
ZA200510252B (en) 2006-12-27
GB0314129D0 (en) 2003-07-23
SA04250169B1 (ar) 2007-08-07
UY28375A1 (es) 2005-01-31
EP1638922A1 (en) 2006-03-29
MXPA05013714A (es) 2006-06-27
JP2006527766A (ja) 2006-12-07
KR20060027348A (ko) 2006-03-27
JP3822900B1 (ja) 2006-09-20
UA81807C2 (uk) 2008-02-11
CA2528932A1 (en) 2004-12-23
TW200503677A (en) 2005-02-01
CN1809529A (zh) 2006-07-26
AU2004247610B2 (en) 2008-04-17
NO20055922L (no) 2006-01-06
US20060142389A1 (en) 2006-06-29
AR044801A1 (es) 2005-10-05
WO2004110984A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
IS8231A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
DK1660431T3 (da) Phenoxyeddikesyrederivater
ATE384696T1 (de) Mandelsäure derivate
NO20050884L (no) Ny fremgangsmate for syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
ATE517887T1 (de) Neue 2-pyridincarbonsäureamidderivate
DE50212761D1 (de) Neuartige aminodicarbonsäurederivate
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20024387L (no) Karboksylsyrederivater som IP-antagonister
NO20043660L (no) Salter av valsartan
EP1765336A4 (en) ANGIOGENESIS INHIBITORS
ATE410407T1 (de) Zimtsäureamidderivate
NO20035694D0 (no) Nye sulfonsyrederivater
ATE384530T1 (de) 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer
NO20054763D0 (no) Salts of clopidogrel and process for preparation
DK1650186T3 (da) Nye dicarboxylsyrederivater
IS8232A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
AP2076A (en) New Heterocyclic carboxylic acid amide derivatives
NO20055485D0 (no) Vannloselige salter av risperidon
PT1513806E (pt) Sais de ácido sulfónico de derivados do ácido mandélico
FI20020593A0 (fi) Menetelmä konjugoidun linolihapon valmistamiseksi
EP1829864A4 (en) ISOCHINOLINE DERIVATIVES AS CALPAININHIBITORS
NO20053673D0 (no) Nye antikonvulsanderivatsalter
NO20050183L (no) Farmasoytiske salter av reboxetin
DK1497290T3 (da) Fremgangsmåde til fremstilling af syresalte af gemifloxacin